Clinical Trial: Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor

U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT07480681) titled 'Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor' on March 13.

Brief Summary: This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic profiles, and preliminary efficacy of HLX97 ( KAT6A/B inhibitor) in patients with advanced/metastatic solid tumors.

Study Start Date: March, 2026

Study Type: INTERVENTIONAL

Condition: Advanced/Metastatic Solid Tumors

Intervention: DRUG: HLX97

HLX 97 will be taken as an oral medication.

DRUG: Fulvest...